logo.jpg
OXURION Confirms Institutional Review Board Approval and Submission of the Investigational New Drug Application to the FDA to Start Phase 2 Study Evaluating THR-687 for Diabetic Macular Edema (DME)
June 10, 2021 01:00 ET | Oxurion NV
THR-687 is a potent pan-RGD integrin antagonistholding potential as next generation first line therapy for DME Leuven, BE, Boston, MA, US – June 10, 2021 – 07.00 AM CET – Oxurion NV (Euronext...
logo.jpg
OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)
June 08, 2021 01:00 ET | Oxurion NV
THR-149 is a potent plasma kallikrein inhibitor for the treatment of DME in the roughly 40% of the patient population responding suboptimally to anti-VEGF therapy Leuven, BE, Boston, MA, US – June 8,...
logo.jpg
OXURION NV Appoints Tom Graney, CFA as Chief Executive Officer
May 17, 2021 01:30 ET | Oxurion NV
Patrik De Haes M.D. becomes Non-executive Chairman Leuven, BE and Boston, MA, US – May 17, 2021 – 7:30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next...
logo.jpg
OXURION NV Presenting Scientific Data at ARVO 2021 Annual Meeting
April 30, 2021 01:30 ET | Oxurion NV
Leuven, BE, Boston, MA, US – April 30st, 2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies with...
logo.jpg
OXURION NV to Present at Wet AMD and DME Drug Development Summit
April 13, 2021 01:30 ET | Oxurion NV
Leuven, BE, Boston, MA, US – April 13th, 2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a...
Oncurious logo.pptx
Oncurious NV Reports Encouraging Data from Phase 1 Dose Escalation Study of TB-403 in Paediatric Subjects with Relapsed or Refractory Medulloblastoma Presented at the American Association for Cancer Research 2021 Annual Meeting
April 12, 2021 01:30 ET | Oxurion NV
Leuven, Belgium, Boston, MA, US, 12 April 2021 – 7.30 AM CET – ONCURIOUS NV, a Belgium-based biotech company focused on developing innovative oncology treatments, today announces that encouraging data...
Oncurious logo.pptx
ONCURIOUS Presenting Clinical and Preclinical Data at Upcoming American Association for Cancer Research (AACR) 2021 Annual Meeting
April 09, 2021 01:38 ET | Oxurion NV
Oral presentation of Phase 1 dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma (MB)Poster presentation of research findings of best therapeutic approach...
logo.jpg
Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD
April 07, 2021 11:45 ET | Oxurion NV
Oxurion is a leader in the development of pan-RGD integrin antagonists for retinal vascular disorders - THR-687 on track to enter Phase 2 development by mid-year Leuven, BE, Boston, MA, US – April 7,...
logo.jpg
Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group
April 06, 2021 01:30 ET | Oxurion NV
Leuven, BE, Boston, MA, US – April 6, 2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care back of the eye therapies,...
logo.jpg
OXURION to Participate in Upcoming Investor Meetings
March 31, 2021 01:30 ET | Oxurion NV
Leuven, BE, Boston, MA, US – March 31st, 2021 – 07.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, today...